In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U ...
Remission and Endoscopic Response with RINVOQ for Advanced and Difficult-to-Treat Crohn's Disease ...
In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular ...
Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III ...
BIAF #BIAF--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company developing noninvasive healthcare ...
(9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study ...
MALMÖ, SE / ACCESS Newswire / October 11, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) today announces that it ...
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 9, 2026
(Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or ...
Investment fuels global expansion of Zaffre® biostimulant and Always N™, reflecting confidence in technology platforms, ...
An archived recording of the fireside chat will be available for 30 days following the event and will be available as a ...
The new award brings together a team of scientists who will combine AI, large-scale experiments and human-cell studies to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results